Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-09-18 Tax Withholding | 2026-09-22 4:24 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Younis Husam Chief Scientific Officer | 11,216 | $8.95 | 41,441 (Direct) | View |
| 2026-09-18 Tax Withholding | 2026-09-22 4:23 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Hughes Steven George Chief Medical Officer | 21,459 | $8.95 | 51,638 (Direct) | View |
| 2026-09-18 Tax Withholding | 2026-09-22 4:20 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Flanagan W. Michael Director | 22,812 | $8.95 | 31,974 (Direct) | View |
| 2026-09-18 Tax Withholding | 2026-09-22 4:20 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Boyce Sarah Director | 126,418 | $8.95 | 138,668 (Direct) | View |
| 2026-09-18 Tax Withholding | 2026-09-22 4:18 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Kenney Stephanie See Remarks | 2,375 | $8.95 | 33,085 (Direct) | View |
| 2026-09-18 Tax Withholding | 2026-09-22 4:17 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Gallagher Kathleen P. See Remarks | 11,632 | $8.95 | 119,729 (Direct) | View |
| 2026-09-18 Tax Withholding | 2026-09-22 4:17 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Winslow Brendan R. Chief Financial Officer | 6,742 | $8.95 | 36,859 (Direct) | View |
| 2026-09-18 Tax Withholding | 2026-09-22 4:15 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Hoyos Rocio Martin Chief Strategy Officer | 8,320 | $8.95 | 38,340 (Direct) | View |
| 2026-04-20 Option Award | 2026-04-22 5:54 pm | N/A 2036-04-20 | Atrium Therapeutics Inc. | RNA | Kenney Stephanie See Remarks | 90,000 | $0 | 95,460 (Direct) | View |
| 2026-04-20 Option Award | 2026-04-22 5:54 pm | N/A 2036-04-20 | Atrium Therapeutics Inc. | RNA | Hughes Steven George Chief Medical Officer | 90,000 | $0 | 133,097 (Direct) | View |
| 2026-04-20 Option Award | 2026-04-22 5:53 pm | N/A 2036-04-20 | Atrium Therapeutics Inc. | RNA | Winslow Brendan R. Chief Financial Officer | 90,000 | $0 | 103,601 (Direct) | View |
| 2026-04-20 Option Award | 2026-04-22 5:43 pm | N/A 2036-04-20 | Atrium Therapeutics Inc. | RNA | Gallagher Kathleen P. See Remarks | 307,500 | $0 | 336,361 (Direct) | View |
| 2026-04-20 Option Award | 2026-04-22 5:41 pm | N/A 2036-04-20 | Atrium Therapeutics Inc. | RNA | Hoyos Rocio Martin Chief Strategy Officer | 90,000 | $0 | 106,660 (Direct) | View |
| 2026-04-20 Option Award | 2026-04-22 5:40 pm | N/A 2036-04-20 | Atrium Therapeutics Inc. | RNA | Younis Husam Chief Scientific Officer | 90,000 | $0 | 112,657 (Direct) | View |
| 2026-02-27 Option Award | 2026-03-02 6:00 pm | N/A 2036-02-27 | Atrium Therapeutics Inc. | RNA | Boyce Sarah Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2026-02-27 Option Award | 2026-03-02 6:00 pm | N/A 2036-02-27 | Atrium Therapeutics Inc. | RNA | BOESS CARSTEN Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2026-02-27 Option Award | 2026-03-02 6:00 pm | N/A 2036-02-27 | Atrium Therapeutics Inc. | RNA | WILSON TROY EDWARD Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2026-02-27 Option Award | 2026-03-02 6:00 pm | N/A 2036-02-27 | Atrium Therapeutics Inc. | RNA | Flanagan W. Michael Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2026-02-27 Option Award | 2026-03-02 6:00 pm | N/A 2036-02-27 | Atrium Therapeutics Inc. | RNA | Skerjanec Simona Director | 20,000 | $0 | 20,000 (Direct) | View |
Ownership | 2026-02-26 6:21 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | WILSON TROY EDWARD Director | 0 | $0 | 11,731 (Direct) | View |
Ownership | 2026-02-26 6:20 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Kenney Stephanie See Remarks | 0 | $0 | 5,460 (Direct) | View |
Ownership | 2026-02-26 6:16 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Flanagan W. Michael Director | 0 | $0 | 54,786 (Direct) | View |
Ownership | 2026-02-26 6:16 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | BOESS CARSTEN Director | 0 | $0 | 11,005 (Direct) | View |
Ownership | 2026-02-26 6:16 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Boyce Sarah Director | 0 | $0 | 265,086 (Direct) | View |
Ownership | 2026-02-26 6:13 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Gallagher Kathleen P. See Remarks | 0 | $0 | 28,861 (Direct) | View |
Ownership | 2026-02-26 6:13 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Winslow Brendan R. Chief Financial Officer | 0 | $0 | 13,601 (Direct) | View |
Ownership | 2026-02-26 6:11 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Younis Husam Chief Scientific Officer | 0 | $0 | 22,657 (Direct) | View |
Ownership | 2026-02-26 6:10 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Skerjanec Simona Director | 0 | $0 | 5,902 (Direct) | View |
Ownership | 2026-02-26 6:06 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Hughes Steven George Chief Medical Officer | 0 | $0 | 43,097 (Direct) | View |
Ownership | 2026-02-26 6:05 pm | N/A N/A | Atrium Therapeutics Inc. | RNA | Hoyos Rocio Martin Chief Strategy Officer | 0 | $0 | 16,660 (Direct) | View |